Heart Failure Heart Team — time to act… now by Zembala, Michał et al.
 
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 
International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they 
credit the authors and the publisher, but without permission to change them in any way or use them commercially. 
 
 
Heart Failure Heart Team — time to act… now 
  
 
Authors: Michał Zembala, Tomasz Hryniewiecki, Krystian Wita, Zbigniew Kalarus, Mariusz 
Gąsior, Marian Zembala 
Article type: Letter to the Editor 
Received: September 22, 2021 
Accepted: October 5, 2021 


















Heart Failure Heart Team — time to act… now 
 
Michał Zembala1, Tomasz Hryniewiecki2, Krystian Wita3, Zbigniew Kalarus1, Mariusz Gąsior1, 
Marian Zembala1 
 
1Silesian Center for Heart Diseases, Zabrze, Poland 
2Cardinal Stefan Wyszyński National Institute of Cardiology, Warsaw, Poland 
3Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University in Katowice, 
Poland 
 
TO THE EDITOR 
The world has changed. Not only due to COVID-19 pandemic and enormous challenges it brought 
along, but also due to clear evidence that postponement means… failure. Heart failure. 
This year, European Society of Cardiology in cooperation with Heart Failure Association (HFA) 
of the ESC released an updated guidelines for the diagnosis and treatment of acute and chronic 
heart failure. While previously published document deepened our knowledge in modern 
pharmacology the 2021 update focuses more on timely action. Experts move away from lengthy 
and (over-) complicated algorithms and point our attention and therapeutic decisions towards more 
simplified, patient-focused approach. The goal is simple: to diagnose and treat myocardial 
dysfunction as soon as possible to prevent patients from developing end-stage heart failure, which 
remain not only difficult to target therapeutically, but more over — has enormous impact on 
healthcare, so severely struck by ongoing pandemic.  
Heart failure affects nowadays almost 65 million people worldwide and this number is expected 
to increase with sustained poor prognosis of advanced heart failure patients despite continuous 
advances in medical management [1]. Heart Transplantation (HTx) holds its strong position as the 
cornerstone of advanced therapy for heart failure. It is the ultimate replacement of the failing organ, 
offering one-year survival of 90% and median survival of 12.5 years with exceptionally good 
quality of life. Yet, long organ waiting time, superbly distressing for individuals placed on elective 
list, has dreadful effects as substantial percent of them expire while waiting. Poland is fortunate in 
this regard, as number heart transplantations has visibly increased over the past 4 years from an 
average of 90–80 to 140–150 cases per annum. Much more is to be improved in terms of early 
morbidity and mortality, which is undoubtedly related to preoperative state of the receipent – often 
referred to HTx late, in poor clinical condition. The same principles apply for mechanical 
circulatory support (MCS). Recently published outcomes of large-volume, multicenter clinical 
trials revealed phenomenal safety profile in contemporary, long-term left ventricular assist devices 
(LVADs) which are now recommended for broader patient population, at early stages of the 
disease. Technological breakthroughs will continue, with wireless charging and connectivity not 
far on the horizon. Yet… perception of unattainability of these therapeutic solutions so often 
dominates our talks and discussions. Assist devices are on-the-shelf, ready to use products 
frequently covered with dust in OR storage. The devices are mobilized when barely alive patient 
is finally rushed to the Transplant Center after weeks of ineffective peripheral mechanical support 
and maximally up-titrated vasoactive and inotropic medications. ESC screams out loud in just-
published guidelines – Don’t wait! Time is of the essence! Team up with centers of excellence, 
create, run and maintain heart failure meetings often where true experts in heart failure review and 
decide on how to proceed with patient diagnosed with heart failure. It is now up to heart team 
decision when and how to treat mitral insufficiency (clip vs surgery), revascularize myocardium 
(PCI vs CABG), implant intravascular or subcutaneous ICD, propose durable or temporary 
mechanical circulatory support or enlist patient for heart transplantation. Countless patients 
frequently fly back to cardiology departments due to exacerbation of myocardial dysfunction and 
are not offered treatment which is in a hand’s reach. Or the opposite — are offered half-way 
solutions which are thrown away as the heart is excised during transplantation couple of weeks 
later. We need to come together as one true heart team: surgeons, cardiologists, anesthesiologist, 
intensivists supported by of social workers, nurses, physiotherapists… as the disease is overly 
complex and requires collaborative and convergent approach.  
Novel guidelines provide patient-centered approach with simplified triage algorithm in which 
patients suffering from HF are directed to centers of excellence in advanced heart failure (AHFC), 
managed in local cardiology service with clinical re-evaluation every 3–6 months or offered 
palliative care option. The realms of end-stage heart failure management model seen before often 
revealed delayed referral where multiorgan failure has already been or finished developing. Again, 
our national efforts to create a network of primary and specialized ambulatory care and out-patient 
clinics collaborating with centers of excellence seem to precede ESC’s guidelines. The concept of 
“Krajowa Sieć Kardiologiczna” (or National Cardiology and Cardiac Surgery Network) answers 
what European Experts advocate for — a broad range, accessible network of centers focused on 
the profound diagnosis and treatment of the disease in its early and advanced stages. Yet, 
concentration of expertise and experience justifies extraordinary spending only if outcomes and 
quality are routinely measured and evaluated (structure, process, and outcome measure) by 
independent agencies or committees.  
This year’s ESC/EACTS heart failure and valvular guidelines are one of the best published. Not 
because they collect the most valuable and accurate clinical and experimental data, not because 
they review and judge the power of registries and trials, not because they emphasize the concept 
of a true heart team, but because they concentrate on the patient. 
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